阿托伐他汀对非酒精性脂肪肝的疗效评价

Effect of atorvastatin in the treatment of nonalcoholic fatty liver disease

目的：探讨阿托伐他汀在非酒精性脂肪肝中的治疗效果及临床应用价值。方法选择非酒精性脂肪肝患者110例，采取随机数字表法分为观察组和对照组（每组55例），对照组给予复方二氯醋酸二异丙胺口服，观察组联合阿托伐他汀治疗，观察两组治疗效果。结果观察组治疗后丙氨酸氨基转氨酶（39．78±3．45）U／L，天冬氨酸氨基转氨酶（29．17±3．17）U／L，γ－谷氨酰胺转肽酶（54．28±4．11）U／L；对照组治疗后丙氨酸氨基转氨酶（52．78±6．81）U／L，天冬氨酸氨基转氨酶（39．96±6．21）U／L，γ－谷氨酰胺转肽酶（68．69±8．31）U／L，组间对比差异均有统计学意义（t＝12．6290、11．4770、11．5273，均P＜0．05）。观察组治疗后甘油三酯（1．66±0．32）mmol／L，总胆固醇（3．27±0．37）mmol／L，低密度脂蛋白（1．94±0．45）mmol／L；对照组治疗后甘油三酯（2．38±0．92） mmol／L，总胆固醇（5．74±1．49） mmol／L，低密度脂蛋白（3．46±1．17）mmol／L，组间对比差异均有统计学意义（t＝5．4818、11．9316、8．9925，均P＜0．05）。观察组治疗后超声评分（1．33±0．12）分，肝／脾CT比值（0．33±0．08）；对照组治疗后超声评分（1．78±0．35）分，肝／脾CT比值（0．47±0．21），组间对比差异均有统计学意义（t＝9．0197、4．6202，均P＜0．05）。结论阿托伐他汀应用在非酒精性脂肪肝中可以有效改善患者肝脏功能，降低血脂浓度，不良反应轻微，值得在临床大力推广使用。

Objective To explore the effect of atorvastatin in the treatment of nonalcoholic fatty liver disease and its clinical application value.Methods 110 patients with nonalcoholic fatty liver disease were randomly divided into observation group and control group,55 cases in each group.The control group was given compound dichloroace-tate diisopropylamine orally,the observation group was given atorvastatin therapy.The effects of the two groups were recorded.Results In the observation group after treatment,the alanine aminotransferase was （39.78 ±3.45） U/L, aspartate aminotransferase was （29.17 ±3.17） U/L,gamma glutamine transpeptidase was （54.28 ±4.11） U/L.In the control group after treatment,the alanine aminotransferase was （52.78 ±6.81） U/L,aspartate aminotransferase was （39.96 ±6.21）U/L,gamma glutamine transpeptidase was （68.69 ±8.31）U/L,there were statistically signifi-cant differences between the two groups（t=12.6290,11.4770,11.5273,all P〈0.05）.In the observation group after treatment,the triglycerides was （1.66 ±0.32）mmol/L,total cholesterol was （3.27 ±0.37）mmol/L,low density lipo-protein was （1.94 ±0.45）mmol/L.In the control group after treatment,the triglycerides was （2.38 ±0.92）mmol/L,total cholesterol was （5.74 ±1.49）mmol/L,low density lipoprotein was （3.46 ±1.17）mmol/L,there were statis-tically significant differences between the two groups（t=5.4818,11.9316,8.9925,all P〈0.05）.In the observation group after treatment,the ultrasonic score was （1.33 ±0.12）,liver/spleen CT ratio was （0.33 ±0.08）.In the con-trol group after treatment,the ultrasonic score was （1.78 ±0.35）,liver/spleen CT ratio was （0.47 ±0.21）,there were statistically significant differences between the two groups（t =9.0197,4.6202,all P ＆lt;0.05）.Conclusion Atorvastatin in the treatment of nonalcoholic fatty liver disease can effectively improve the liver function,reduce blood lipid concentration,minor adverse reactions,and it is worth popularizing in clinical use.